Boston Scientific Corporation (BSX) Stock Forecast
BSX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.39 / 5 from 31 analysts
- Price target
- $59.24 average of analyst targets
- Upside to target
- +33.5% from the latest close
- Next earnings
- October 28, 2026 EPS estimate $0.76
- 52-week range
- $41.58 – $104.98
BSX analyst ratings
31 analystsNumber of analysts at each rating.
BSX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BSX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.74 | $0.58 | $0.82 | $0.75 | −1.1% | 24 |
| Current fiscal year (2026) | $3.24 | $3.11 | $3.37 | $3.06 | +6.0% | 27 |
| Next fiscal year (2027) | $3.38 | $3.19 | $3.62 | $3.24 | +4.1% | 27 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BSX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $5.09B | $4.70B | $5.30B | +0.5% | 24 |
| Current fiscal year (2026) | $21.16B | $20.75B | $21.57B | +5.4% | 27 |
| Next fiscal year (2027) | $22.19B | $21.59B | $23.70B | +4.9% | 28 |
BSX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BSX revenue: reported and forecast
BSX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.84 | $0.81 | $0.78 | $0.75 | $0.74 | −11.2% | 0 up · 11 down |
| Current fiscal year (2026) | $3.36 | $3.30 | $3.29 | $3.26 | $3.24 | −3.4% | 0 up · 11 down |
| Next fiscal year (2027) | $3.71 | $3.44 | $3.43 | $3.38 | $3.38 | −8.9% | 0 up · 11 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BSX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BSX beat in 12 of 12.
What analysts expect from BSX
31 analysts cover Boston Scientific; their consensus rating is buy (4.39 on a 1–5 scale, where 5 is a strong buy). The average price target is $59.24, 33.5% above the latest close of $44.39. Analysts expect earnings of $3.24 per share for 2026, +6.0% from a year earlier. For 2027 the average estimate is $3.38 per share on revenue of $22.2 billion. Boston Scientific beat the EPS estimate in 12 of the last 12 quarters.
Related: BSX income statement, BSX key metrics, BSX chart. See the BSX stock overview for the latest quote and news.
BSX forecast FAQ
What is Boston Scientific's price target?
The average analyst price target for Boston Scientific is $59.24, 33.5% above the latest close of $44.39.
Is Boston Scientific a buy, hold or sell?
Of 31 analysts covering Boston Scientific, 18 rate it a strong buy, 7 a buy, 6 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Boston Scientific's EPS forecast?
Analysts forecast $3.24 per share for 2026 (range $3.11 to $3.37); for 2027 the estimate is $3.38.
What is Boston Scientific's revenue forecast?
The average revenue estimate for 2026 is $21.2 billion, growth of 5.4%; for 2027 it is $22.2 billion.
When does Boston Scientific report earnings?
Boston Scientific is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 before the market opens; the EPS estimate is $0.76.
Does Boston Scientific usually beat earnings estimates?
Boston Scientific reported EPS at or above the analyst estimate in 12 of the last 12 quarters.